Cabozantinib & Pain in Prostate Cancer – an interview with Dr Maha Hussain
Maha Hussain MB ChB is Professor of Medical Oncology at the University of Michigan. She is an international expert into genitourinary malignancies with a focus on clinical research into prostate and bladder cancer.
Cabozantinib is a new drug in development by Exelixis for multiple indications. It captured a lot of attention at the ASCO 2011 annual meeting last year, when Dr Hussain presented data from a phase 2 prostate cancer trial that showed a dramatic improvement in bone scans and pain reduction in those men receiving it.
The recent AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics international conference in San Francisco was an informative meeting.